Results 51 to 60 of about 25,722,272 (279)
Nature CommunicationsDiabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu +11 more
doaj +1 more source
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
Biomolecules, 2022 Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia and associated with an increased risk of morbidity and mortality, primarily from cardiovascular and renal diseases. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is)
Francesca Romana Prandi +8 more
doaj +1 more source
Golgi enzymes are retrieved from the plasma membrane to the trans‐Golgi network
FEBS Letters, EarlyView.Golgi enzymes are traditionally considered resident proteins retained within the Golgi apparatus. Here, we demonstrate that a subset transiently reaches the cell surface and is subsequently retrieved to the trans‐Golgi network via retrograde transport. Using a nanobody‐based toolkit, we uncover a dynamic trafficking cycle of several Golgi enzymes.
Dominik P. Buser, Tina Junne
wiley +1 more source
Effect of sodium-glucose transporter 2 inhibitors on bone
Journal of Parathyroid Disease, 2023 Diabetes mellitus is a common illness, and the number of people affected by this condition is expected to increase significantly. Complications associated with type 2 diabetes mellitus, such as cataracts, retinopathy, neuropathy, and orthostatic hypotension, can increase the risk of falls and subsequent bone fractures.
Mahdi Baradaranfard, Taha Ameli
openaire +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Journal of Obesity & Metabolic Syndrome, 2021 Background : We aimed to evaluate the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for managing obesity in non-diabetic overweight or obese patients.
Yun Kyung Cho +2 more
doaj +1 more source
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor [PDF]
Korean Journal of Medicine, 2014 Correspondence to Jeong Hyun Park, M.D., Ph.D. Paik Institute for Clinical Research, Department of Internal Medicine, Pusan Paik Hospital, Inje University College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 614-735, Korea Tel: +82-51-890-6074, Fax: +82-51-892-0273, E-mail: pjhdoc@chol.com Copyrightc 2014 The Korean Association of Internal Medicine ...
Mi-kyung Kim, Jeong Hyun Park
openaire +1 more source
FEBS Open Bio, EarlyView.In normal (nontolerant) cells, CD14 is crucial for both LPS uptake and LPS signaling. In LPS‐tolerant cells, in which LPS‐induced TNF‐α and IFN‐β production is suppressed, there is a dramatic increase in surface CD14 expression. The overexpressed CD14 in LPS‐tolerant cells is responsible for the enhanced LPS uptake without inducing pro‐inflammatory ...
Saeka Nishihara +3 more
wiley +1 more source
SGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Revista Portuguesa de Nefrologia e Hipertensão, 2023 Introduction: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have shown positive renal outcomes in diabetic patients. There is also emerging evidence in non-diabetic patients.
Mariana Silva de Sousa +5 more
doaj +1 more source
, 2014 Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin ...
Joshua J Neumiller
core +1 more source